Lyra Therapeutics

Lyra Therapeutics, headquartered in Boston and formerly known as 480 Biomedical, is a clinical-stage biotechnology company. Lyra focuses on developing medications for ear, nose, and throat (ENT) diseases, as well as designing alternatives to traditional treatments or surgeries. Its lead candidate drug, LYR-210, delivers anti-inflammatory medication deep into nasal tissues for up to six months of treatment. Lyra utilizes proprietary technologies in drug development and material science to create a transmucosal therapeutic system (a polymer matrix-based drug delivery system) that enables targeted treatment at inflammatory sites within the nasal and sinus passages.The Lyra Therapeutics team, with expertise in material science, drug development, and formulation, has developed a proprietary technology platform. This platform aims to enable long-acting localized drug delivery directly to affected tissues. Based on clinical outcomes in chronic rhinosinusitis (CRS), this novel treatment approach holds the potential to address the currently limited treatment and surgical options for ENT conditions, significantly improving patient outcomes.